secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-07-25T23:59:59+00:00
Accession:  0001551152-24-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q2 adj EPS $2.65, revenue $14.46B; raises FY2024 adj EPS guidance to $10.71-$10.91
--------------------------------------------------------------------------------

- Q2 GAAP EPS $0.77 (down 32.5% YoY); adjusted EPS $2.65 (down 8.9% YoY), including $0.52 IPR&D impact.
- Net revenue $14.462B (+4.3% reported, +5.6% operational); Immunology up 2.3% as Humira -29.8% offset by Skyrizi +44.8% and Rinvoq +55.8%.
- Neuroscience portfolio up 14.7% to $2.162B; Aesthetics flat at $1.390B.
- FY2024 adjusted EPS guidance raised to $10.71-$10.91 from $10.61-$10.81, including $0.60 IPR&D impact.
- Recent events: Robert Michael became CEO July 1; FDA approved Skyrizi for UC; FDA CRL for ABBV-951 Parkinson's; acquisitions of Landos and Celsius.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000026/0001551152-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115224000026/abbv-20240725.htm
  HTML page:      https://secwatch.observer/filing/0001551152-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer